Skip to main content

Increasing the potency of vaccinia MVA vaccines

Objective

Clinical trials using modified Vaccinia Virus Ankara (MVA) recombinants against HIV, malaria and tumours are currently underway. To keep a European leading role in the future use of MVA, it will be necessary to introduce modifications in the vector to improve its potency as immunogen. The objective of this project is to develop more immogenic MVA vaccines by:
1) better understanding the biology of the virus;
2) deleting virus immunomodulatory proteins;
3) increasing the virus susceptibility to interferons;
4) effectively displaying antigens on the surface of the virus or cells;
5) expressing host cytokines.

The pathogenis and immune response triggered by the modified MVA will be tested in animal models with vectors expressing relevant antigens from HIV, Plasmodium and tumours. These studies will generate more potent MVA vectors for developing future European Vaccines.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Address
Campus De La Universidad Autonoma De Madrid
28049 Madrid
Spain

Participants (4)

EUROPEAN MOLECULAR BIOLOGY LABORATORY
Germany
Address
Meyerhofstraße 1
69117 Heidelberg
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
United Kingdom
Address
The Wright-fleming Institute, St. Mary's Campus, N
W2 1PG London
INSTITUTO NACIONAL DE INVESTIGACION Y TECNOLOGIA AGRARIA Y ALIMENTARIA
Spain
Address
Carretera De La Coruça Km7.5
28040 Madrid
PAUL-EHRLICH-INSTITUT, FEDERAL AGENCY FOR SERA AND VACCINES
Germany
Address
Paul-ehrlich-strasse 51-59
63225 Langen